Innovation in drug toxicology: Application of mass spectrometry imaging technology
Abstract
Mass spectrometry imaging (MSI) is a powerful molecular imaging technology that can obtain qualitative, quantitative, and location information by simultaneously detecting and mapping endogenous or exogenous molecules in biological tissue slices without specific chemical labeling or complex sample pretreatment. This article reviews the progress made in MSI and its application in drug toxicology research, including the tissue distribution of toxic drugs and their metabolites, the target organs (liver, kidney, lung, eye, and central nervous system) of toxic drugs, the discovery of toxicity-associated biomarkers, and explanations of the mechanisms of drug toxicity when MSI is combined with the cutting-edge omics methodologies. The unique advantages and broad prospects of this technology have been fully demonstrated to further promote its wider use in the field of pharmaceutical toxicology.
- Publication:
-
Toxicology
- Pub Date:
- December 2021
- DOI:
- 10.1016/j.tox.2021.153000
- Bibcode:
- 2021Toxgy.46453000J
- Keywords:
-
- MSI;
- mass spectrometry imaging;
- QWBA;
- quantitative whole-body autoradiography;
- FC;
- fold change;
- m/z;
- mass-to-charge ratio;
- ROIs;
- regions of interest;
- PCA;
- principal component analysis;
- OPLS-DA;
- orthogonal-partial least squares discrimination analysis;
- LC–MS;
- liquid chromatography mass spectrometry;
- NMR;
- nuclear magnetic resonance;
- mPGES-1;
- microsomal prostaglandin E synthase 1 inhibitors;
- LDI;
- laser desorption ionization;
- MALDI;
- matrix-assisted laser desorption/ionization;
- DAB;
- dabrafenib;
- MALDI-TOF;
- matrix assisted laser desorption/ionization time-of-flight;
- DESI;
- desorption electrospray ionization;
- LA-ICP-MSI;
- laser ablation inductively coupled plasma mass spectrometry imaging;
- OCT2;
- organic cation transporter 2;
- PMBN;
- polymyxin B nonapeptide;
- CYP2E1;
- cytochromeP450 2E1;
- APAP;
- acetaminophen;
- GSH;
- glutathione;
- APAP-SUL;
- acetaminophen sulfate;
- APAP-GLC;
- acetaminophen glucuronide;
- CCl<SUB>4</SUB>;
- carbon tetrachloride;
- SIMS;
- secondary ion mass spectrometry;
- di-22:6-BMP;
- di-docosahexaenoyl (22:6)-bis(monoacylglycerol) phosphate;
- di-22:6 PG;
- di-docosahexaenoic (22:6 n-3) phosphatidylglycerol;
- SiO<SUB>2</SUB>-n;
- amorphous silica nanoparticles;
- SiO<SUB>2</SUB>-p;
- phosphonate-coated silica nanoparticles;
- BAK;
- benzalkonium chloride;
- LPCs;
- lyso phosphatidylcholines;
- PD;
- Parkinson's disease;
- MPTP;
- 1-methyl-4-phenyl-1;
- 2;
- 3;
- 6-tetrahydropyridine;
- MPP<SUP>+</SUP>;
- 1-methyl-4-phenylpyridine ion;
- AFADESI-MSI;
- airflow-assisted desorption electrospray ionization mass spectrometry imaging;
- AAI;
- aristolochic acids I;
- BPF;
- bisphenol F;
- GPs;
- glycerophospholipids;
- GLs;
- glycerolipids;
- MGs;
- monoglycerols;
- DGs;
- diacylglycerols;
- PCs;
- phosphatidylcholines;
- PIs;
- phosphatidylinositols;
- PEs;
- phosphatidylethanolamines;
- TAGs;
- triacylglycerols;
- BMPs;
- bisphosphates;
- BMAA;
- β-N-methylamino-L-alanine;
- ATP;
- adenosine triphosphate;
- ADP;
- adenosine diphosphate;
- AMP;
- adenosine monophosphate;
- NADH;
- nicotinamide adenine dinucleotide;
- CE;
- capillary electrophoresis;
- BPS;
- bisphenol S;
- PGs;
- phosphatidylglycerols;
- SMs;
- sphingomyelins;
- Cers;
- ceramides;
- So;
- sphingosine;
- PSs;
- phosphatidylserines;
- EFV;
- efavirenz;
- TFV;
- tenofovir;
- FTC;
- emtricitabine;
- FDV;
- Fosdevirine;
- DESI/PI-MSI;
- desorption electrospray ionization/postphotoionization mass spectrometry imaging;
- Mass spectrometry imaging (MSI);
- Drug toxicology;
- Organ toxicity;
- Biomarkers;
- Toxicological mechanisms